Company news
Kura Oncology, Inc. news in 2021
Kura Oncology, Inc.'s news releases, calls and decks from 2021, newest first.
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
December 15, 2021
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
December 12, 2021
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
December 12, 2021
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
November 23, 2021
Kura Oncology Reports Third Quarter 2021 Financial Results
November 3, 2021
Kura Oncology to Participate in Credit Suisse Healthcare Conference
November 1, 2021
Kura Oncology to Report Third Quarter 2021 Financial Results
October 27, 2021
Kura Oncology Appoints Teresa Bair as Chief Legal Officer
October 17, 2021
Kura Oncology Reports Second Quarter 2021 Financial Results
August 4, 2021
Kura Oncology to Report Second Quarter 2021 Financial Results
July 28, 2021
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
July 28, 2021
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
July 5, 2021
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
June 23, 2021
Kura Oncology to Participate in JMP Securities Life Sciences Conference
June 9, 2021
Kura Oncology Appoints Carol Schafer to Board of Directors
June 3, 2021
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
May 12, 2021
Kura Oncology Reports First Quarter 2021 Financial Results
May 5, 2021
Kura Oncology to Report First Quarter 2021 Financial Results
April 28, 2021
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
March 21, 2021
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
February 23, 2021
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
February 23, 2021
Kura Oncology to Participate in Four Upcoming Investor Conferences
February 17, 2021
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
February 16, 2021
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
January 6, 2021
Kura Oncology to Present at J.P. Morgan Healthcare Conference
January 5, 2021
Calls in 2021
Decks in 2021
- ASH 2021
Conference · 18 slides · 2021
- Technical Presentation (2021)
Technical · 9 slides · 2021